Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of Dupilumab in the Treatment of Patients with Uncontrolled Severe CRSwNP: A “Real-Life” Observational Study in Naïve and Post-Surgical Patients
Giancarlo Ottaviano, Tommaso Saccardo, Giuseppe Roccuzzo, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 9, pp. 1526-1526
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience
Cosimo Galletti, Federico Sireci, Giovanna Stilo, et al.
American Journal of Otolaryngology (2025) Vol. 46, Iss. 1, pp. 104597-104597
Open Access | Times Cited: 2
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
Corrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 29
Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care
Cosimo Galletti, María Antonietta Barbieri, Francesco Ciodaro, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 630-630
Open Access | Times Cited: 24
Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy
Tobias Albrecht, Martin M. Sailer, Flavia Capitani, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 5, pp. 100780-100780
Open Access | Times Cited: 23
Real‐World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps
Marisa Dorling, Juan Carlos Hernaiz‐Leonardo, Athenea Pascual, et al.
The Laryngoscope (2024) Vol. 134, Iss. 7, pp. 3054-3059
Open Access | Times Cited: 14
Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature
Marella Reale, Giuseppe Licci, Pietro Orlando, et al.
European Archives of Oto-Rhino-Laryngology (2024) Vol. 281, Iss. 10, pp. 5023-5031
Closed Access | Times Cited: 9
Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis
Miguel Rodriguez-Iglesias, Christian Calvo‐Henríquez, Daniel Martín-Jiménez, et al.
Current Allergy and Asthma Reports (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta‐Analysis of Real‐World Evidence
Shiru Cai, Shenglong Xu, Yan Zhao, et al.
Allergy (2025)
Open Access | Times Cited: 1
Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
Mu Xian, Bing Yan, Xicheng Song, et al.
Allergy (2025)
Open Access | Times Cited: 1
Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience
Cosimo Galletti, Martina Ragusa, Federico Sireci, et al.
American Journal of Otolaryngology (2023) Vol. 45, Iss. 1, pp. 104106-104106
Open Access | Times Cited: 19
Biologics for Chronic Rhinosinusitis—A Modern Option for Therapy
Romică Cergan, Ovidiu Berghi, Mihai Dumitru, et al.
Life (2023) Vol. 13, Iss. 11, pp. 2165-2165
Open Access | Times Cited: 19
How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review
Eugenio De Corso, Stefano Settimi, Claudio Montuori, et al.
Acta Otorhinolaryngologica Italica (2023) Vol. 43, Iss. 2 (Suppl. 1), pp. S3-S13
Open Access | Times Cited: 17
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence
Marco Caminati, Claudio Micheletto, Francesca Norelli, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 15-23
Closed Access | Times Cited: 7
Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care
Cosimo Galletti, Francesco Ciodaro, María Antonietta Barbieri, et al.
American Journal of Otolaryngology (2024) Vol. 45, Iss. 4, pp. 104329-104329
Closed Access | Times Cited: 6
Influence of Prior Endoscopic Sinus Surgery Extent on Dupilumab Effectiveness in CRSwNP Patients
Matteo Alicandri‐Ciufelli, Daniele Marchioni, Carlotta Pipolo, et al.
The Laryngoscope (2023) Vol. 134, Iss. 4, pp. 1556-1563
Open Access | Times Cited: 15
Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52
Claus Bachert, Asif Khan, Stella E. Lee, et al.
International Forum of Allergy & Rhinology (2023) Vol. 14, Iss. 3, pp. 668-678
Open Access | Times Cited: 14
Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life
Antonella Loperfido, Andrea Ciofalo, Carlo Cavaliere, et al.
Journal of Immunology Research (2023) Vol. 2023, pp. 1-10
Open Access | Times Cited: 13
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps
Marco Caminati, Eugenio De Corso, Giancarlo Ottaviano, et al.
Current Allergy and Asthma Reports (2023) Vol. 24, Iss. 1, pp. 11-23
Open Access | Times Cited: 13
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter
Francesca Norelli, Michele Schiappoli, Gianenrico Senna, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1066-1066
Open Access | Times Cited: 5
Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
Giovanna Piazzetta, Nadia Lobello, Emanuela Chiarella, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 9, pp. 1404-1404
Open Access | Times Cited: 12
Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience.
Gianluca Bellocchi, Antonella Loperfido, Francesco Maria Passàli, et al.
PubMed (2023) Vol. 94, Iss. 5, pp. e2023227-e2023227
Closed Access | Times Cited: 11
Biological therapy in Chronic rhinosinusitis with nasal polyps
Zeyi Jin, Bing Yan, Luo Zhang, et al.
Expert Review of Clinical Immunology (2025)
Closed Access
Impact of single versus multiple surgeries in CRSwNP patients undergoing treatment with dupilumab
Matteo Alicandri‐Ciufelli, Carla Cantaffa, Costanza Galloni, et al.
Acta Oto-Laryngologica (2025), pp. 1-7
Closed Access
Sustained Efficacy and Low Rate of Adverse Events of Dupilumab in Type‐2 CRSwNP Over 48 Months
Pietro Orlando, Giuseppe Licci, Gennaro Illiano, et al.
The Laryngoscope (2025)
Closed Access
Raccomandazioni pratiche nella gestione ambulatoriale della rinosinusite cronica con poliposi nasale severa, nell’era dei biologici
Eugenio De Corso, Carlotta Pipolo, Elena Cantone, et al.
Acta Otorhinolaryngologica Italica (2023) Vol. 43, Iss. 5, pp. 324-340
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top